New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and ...

These variations reflect differences in reimbursement policies for Lp apheresis rather than differences in the prevalence of drug-refractory familial hypercholesterolemia (FH), the main indication ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and ...

This study aims to address several key questions regarding the use of inclisiran in real-world clinical practice in Spain. The objective of the study is to determine the proportion of Atherosclerotic ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol.

That will fund operations until 2026, beyond the readout of phase 3 trials including the BROADWAY study of obicetrapib in adults with heterozygous familial hypercholesterolaemia (HeFH) and/or ...

The prevalence of type 2 diabetes mellitus is growing worldwide. By the year 2020, 250 million people will be afflicted1. Most forms of type 2 diabetes are polygenic with complex inheritance ...

Ford et al. examined NHANE surveys from 1999–2006 and found that the unadjusted prevalence of hypercholesterolemia remained relatively steady over the study period, ranging from 53.2 to 56.1% in ...

A phase 1b showed promising results in lowering LDL in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease. Read More. Protein Responsible for Parkinson’s ...